Mounjaro

• 1/29/2025

  Cancer Breakthrough: Eli Lilly’s $533 Billion Opportunity

• 1/23/2025

  Is Eli Lilly’s Slump a Hidden Buying Opportunity?

• 1/19/2025

  Eli Lilly’s Revenue Outlook Shifts Amidst GLP-1RA Market Volatility

• 1/18/2025

  Eli Lilly’s Revenue Outlook Slumps Amidst Fierce Competition

• 1/16/2025

  Eli Lilly’s Q4 Revenue Guidance Falls Short, Shares Tumble 6%

• 12/23/2024

  FDA Greenlights Revolutionary Sleep Apnea Treatment, Offering New Hope to Millions

• 11/23/2024

  Eli Lilly and Pfizer: What’s Next for Big Pharma’s Powerhouses?

• 11/13/2024

  Weight-Loss Giants Face Uncertainty: Can They Adapt to Changing Market?

• 11/10/2024

  Eli Lilly Stock: High Expectations Meet Reality Check

• 11/1/2024

  Eli Lilly’s Weight Loss and Diabetes Drugs Miss Sales Expectations Amid Inventory Issues